Monitor for any new U.S. government TPOXX contract, which is the primary revenue driver. The Canadian contract provides modest backlog but does not replace the U.S. SNS orders that drove prior-year results.
Drug in focus
SIGA drug pipeline →TPOXX
● Neutral Named in this press release- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially available (oral since 2018, IV since 2022).
- Next catalyst
- None dated
What to watchThe next hard catalyst is Q3 2026 earnings on November 5, 2026, which will show whether TPOXX deliveries continued and whether management has secured a new multi-year BARDA procurement contract. Without a new contract, the revenue cliff from the nearly-exhausted 19C contract is the dominant risk. The longer-term catalyst is the planned FDA submission for post-exposure prophylaxis in H1 2027, but that is over six months away and not yet a binary event.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $3.13entry
- T+1 · 6d ago +0.32%α −1.00% · $3.14
- T+4 · todayOpen
- T+5 · in 4h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
SIGA reported Q3 2026 revenue of $1.3M, down 50% YoY from $2.6M, and a net loss of $2.9M ($0.04 per share) vs. a $6.4M loss a year ago. The company highlighted a $15M Canadian procurement contract for oral TPOXX and the retirement of its Chief Scientific Officer, but the sharp revenue decline and lack of a new U.S. government contract weigh on the outlook.
Key Financial Metrics
Key Facts
- Q3 2026 total revenues $1.3M vs $2.6M in Q3 2025, a 50% decline
- Q3 2026 net loss $2.9M ($0.04 per share) vs $6.4M loss ($0.09) in Q3 2025
- Nine-month 2026 product sales $41.6M vs $85.8M in the prior year period
- Awarded $15M Canadian DND contract for oral TPOXX, with $9M firm commitments over 3 years
- Chief Scientific Officer Dennis Hruby retired after 30+ years
- Cash and equivalents $116.4M at Sept 30, 2026, down from $155.0M at Dec 31, 2025
- No new U.S. government TPOXX procurement contract announced
Financial Impact
Q3 revenue fell 50% YoY to $1.3M; nine-month revenue down 46% to $48.6M; net loss of $2.9M in Q3 vs $6.4M loss a year ago
Risk Factors
- No new U.S. government procurement contract for TPOXX, the main revenue source
- International biodefense market development is uncertain and may not offset U.S. demand decline
- Cash burn: cash decreased $38.6M from year-end 2025 to $116.4M, partly due to $0.60 special dividend
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3398911 |
Track record
6 reports on SIGA
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 9, 20267d ago Press Release Bearish 5/10 Viewing Entry $3.13 to $3.14 Now $2.85 +8.95% ▼ −0.32% +1.00% vs SPY
- Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $3.15 to $2.97 Now $2.85 −9.52% ▼ −5.71% −1.31% vs SPY
- Oct 28, 202619d ago Press Release Neutral 3/10 Entry $3.31 to $3.18 Now $2.85 −13.90% ▼ −3.93% −3.55% vs SPY
- May 8, 202627w ago DEFA14A Neutral 2/10 Entry $4.55 to $4.55 Now $2.85 −37.36% · 0.00% +0.14% vs SPY
- May 7, 202627w ago Press Release Bearish 6/10 Entry $4.80 to $4.55 Now $2.85 +40.63% ▲ +5.21% +5.44% vs SPY
- Mar 26, 202633w ago Press Release Neutral 4/10 Entry $4.69 to $4.65 Now $2.85 −39.21% ▼ −0.75% −0.40% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers